THBD and COVID-19: Likewise, the higher circulating levels of thrombomodulin in COVID-19-although non-significant after removal of immune deficient patients-may reflect augmented shedding from the endothelial cell surface, which is expected to result in a loss of its cell-associated anticoagulant properties.31